profit from every $100 of sales.
$0$100
Integer
$126.70+0.22% today
+86.2% in 1 year
1-year low $67.101-year high $126.75
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $41.90 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Integer sold, what it kept, and what it did with the cash.
Sales went from $1.33 billion in 2022 to $1.85 billion in 2025, with $103 million of profit last year.
SalesProfit
Integer handed back 48% of the cash it generated last year.
Buybacks $50M
Free cash flow 2025$105M
Bought back its own shares$50M
Paid as dividends–
Cash vs. debt$17M vs. $1.3B
Integer vs. similar companies
Integer grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Integer | 41.9× · Expensive | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Integer's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,073 | 1,221 | 1,331 | 1,556 | 1,717 | 1,854 | |
| 286 | 337 | 346 | 410 | 459 | 500 | |
| – | – | 128 | 175 | 220 | 239 | |
| 204 | 214 | 198 | 255 | 311 | 292 | |
| 77 | 97 | 66 | 91 | 120 | 103 | |
| 2.33 | 2.91 | 1.99 | 2.69 | 3.36 | 2.89 | |
| 26.6% | 27.6% | 26.0% | 26.3% | 26.7% | 27.0% | |
| – | – | 9.6% | 11.2% | 12.8% | 12.9% | |
| 7.2% | 7.9% | 5.0% | 5.8% | 7.0% | 5.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,372 | 2,582 | 2,794 | 2,943 | 3,078 | 3,411 |
| Cash | 49 | 18 | 24 | 24 | 47 | 17 |
| Total debt | 778 | 906 | 1,009 | 1,053 | 1,104 | 1,313 |
| Total liabilities | 1,101 | 1,228 | 1,377 | 1,424 | 1,459 | 1,664 |
| 1,271 | 1,355 | 1,417 | 1,519 | 1,619 | 1,747 | |
| 33 | 33 | 33 | 34 | 36 | 36 | |
| 4.8% | 4.6% | 3.4% | 4.8% | 5.8% | 4.2% | |
| 6.1% | 7.1% | 4.7% | 6.0% | 7.4% | 5.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 181 | 157 | 116 | 180 | 205 | 196 | |
| 47 | 53 | 75 | 120 | 105 | 91 | |
| 135 | 103 | 42 | 60 | 100 | 105 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | 0 | 0 | 50 | |
| 9 | 16 | 21 | 23 | 25 | 23 |
Valuation
- 41.9×
- 20.5×
- 9.52
- 1.8×
- 2.3×
- 41.0×
- 19.2×
- 2.4%
- 2.4%
- 0.0%
Profitability
- 27.0%
- 12.9%
- 5.5%
- 17.8%
- 5.4%
- 3.6%
- 8.2%
- 4.2%
- 6.0%
- 2.8%
Growth
- +11.5%
- +4.4%
- +5.5%
- –
- +1.3%
Financial health
- 4.2×
- 0.81
- 40.5%
- 5.1×
- 3.75
- 2.38
- 0.54
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 46%of 964
Top 45%of 898
Bottom 30%of 651
Top 47%of 911
Top 43%of 991
What analysts expect
- Average price target
- $98.00
- Range
- $95.00 – $101.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.20 | 1.21 | −0.8% |
| Feb 19, 2026 | 1.76 | 1.70 | +3.5% |
| Oct 23, 2025 | 1.79 | 1.68 | +6.5% |
| Jul 24, 2025 | 1.55 | 1.57 | −1.3% |
| Apr 24, 2025 | 1.31 | 1.27 | +3.1% |
| Feb 20, 2025 | 1.43 | 1.46 | −2.1% |
| Oct 24, 2024 | 1.43 | 1.36 | +5.1% |
| Jul 25, 2024 | 1.30 | 1.24 | +4.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
54No pass
Philip Fisher
29No pass
Peter Lynch
23No pass
Joel Greenblatt
3No pass
Charlie Munger
23No pass
Terry Smith
30No pass
Questions about Integer
Is Integer a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Integer AI analysis
What does Integer do?
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. It is in Medical - Devices, based in Plano, TX, United States, with 11,000 employees.
Does Integer pay a dividend?
No. Integer does not pay a dividend at the moment; in 2025 it returned $50.0 million to shareholders by buying back its own shares.
Is Integer stock halal?
Questionable. Integer sits in a grey zone: its debt is 31% of its market value, between 30% and 33%. How we check
How has Integer stock done over the past year?
Up 86.2% over the past twelve months, to $126.70. It traded between $67.10 and $126.75, close to its high.
Who are Integer's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Integer's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.